- /
- Supported exchanges
- / F
- / PFEB.F
PFIZER INC.CDR REG.S (PFEB F) stock market data APIs
PFIZER INC.CDR REG.S Financial Data Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. has strategic collaboration with Boltz, PBC to develop and deploy state-of-the-art biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get PFIZER INC.CDR REG.S data using free add-ons & libraries
Get PFIZER INC.CDR REG.S Fundamental Data
PFIZER INC.CDR REG.S Fundamental data includes:
- Net Revenue: 62 785 M
- EBITDA: 24 459 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
PFIZER INC.CDR REG.S News
New
Novavax Licenses Rights to Key Vaccine Component to Pfizer
Novavax, the Covid-19 vaccine maker, has licensed the rights for a vaccine-enhancing component to Pfizer. Pfizer agreed to pay $30 million upfront, and could pay up to $500 million more if development...
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change INVO Fertility Inc. 150,334,936...
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through open science, a new public-private partnership with a...
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?
CorMedix CRMD and Mirum Pharmaceuticals MIRM appeal to investors drawn to the rare-disease biotech space, where smaller patient populations can still translate into meaningful revenue opportunities th...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.